NCT07343076Not yet recruiting
Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)
Source: ClinicalTrials.gov · Last updated 30 Jan 2026
Brief summary (registry, in English)
This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD). NSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form: Intervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing). Control group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1904 (estimated)
- First submitted
- 6 Jan 2026
- Start date
- Feb 2026
- Primary completion date
- Feb 2029
- Lead sponsor
- RenJi Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07343076
What you commit to
- Study type: Interventional
- Planned participants: 1904
- From Feb 2026 to the primary completion date, Feb 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received thrombolytic treatment.
- Previous PCI within the past 1 month or previous coronary artery bypass graft (CABG).
Other illness
- Accompanied by other diseases that lead to an expected survival time of ≤ 12 months.
- Patients with severe valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension.
- Not suitable for clinical study:
- Have enrolled in the other clinical studies that may affect the outcome assessment of this study.
- Pregnant and lactating women.
- Known allergy to the drugs that may be used in the study.
- Unable to comply with the trial protocol or follow-up requirements; or the investigator believes that participation in the trial may put the patient at greater risk.
Lab values
- Patients with other serious diseases such as severe renal insufficiency (creatinine clearance value \<30ml/min), hepatic insufficiency, thrombocytopenia (≤50\*109/L).
Other
- Cardiogenic shock or SBP\< 90 mmHg.
- Patients in whom the culprit vessel cannot be clearly identified.
- Left main coronary artery lesion, non-infarct-related arteries are CTO lesions or severely calcified lesions, complex lesions that require the use of special devices such as rotational ablation/laser.
Who the study is looking for
- Age: 18 years or older.
- Patients with intermediate-to-high risk NSTE-ACS who meet the diagnostic criteria specified in current guideline, complicated by multivessel coronary artery disease, and have successfully undergone PCI for the culprit vessel.
- PCI within 72 hours of diagnosis.
- Accompanied by multivessel disease: defined as at least one non-culprit artery that meets the following conditions: a diameter of ≥2.5 mm by visual inspection, which can be successfully subjected to PCI, and the most severe diameter stenosis rate by visual inspection is at least 70% or positive coronary physiology testing.
- Sign an informed consent form before participating in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.